Cargando…

Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study

BACKGROUND AND RATIONALE: Little is known about SARS-CoV-2 seroconversion in asymptomatic patients affected by solid cancer, and whether it is associated with specific transcriptomics changes in peripheral blood mononuclear cells (PBMC). METHODS: Patients affected by solid cancer treated in a top co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravera, Francesco, Borea, Roberto, Cirmena, Gabriella, Dameri, Martina, Ferrando, Lorenzo, Gallo, Maurizio, Casini, Cecilia, Fallani, Neri, Stabile, Mario, Barbero, Valentina, Murialdo, Roberto, Tixi, Lucia, Cappuccio, Margherita, Cuboni, Andrea, Sivieri, Irene, Fornarini, Giuseppe, De Maria, Andrea, Ballestrero, Alberto, Zoppoli, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107211/
https://www.ncbi.nlm.nih.gov/pubmed/35568887
http://dx.doi.org/10.1186/s12967-022-03429-0
_version_ 1784708441873317888
author Ravera, Francesco
Borea, Roberto
Cirmena, Gabriella
Dameri, Martina
Ferrando, Lorenzo
Gallo, Maurizio
Casini, Cecilia
Fallani, Neri
Stabile, Mario
Barbero, Valentina
Murialdo, Roberto
Tixi, Lucia
Cappuccio, Margherita
Cuboni, Andrea
Sivieri, Irene
Fornarini, Giuseppe
De Maria, Andrea
Ballestrero, Alberto
Zoppoli, Gabriele
author_facet Ravera, Francesco
Borea, Roberto
Cirmena, Gabriella
Dameri, Martina
Ferrando, Lorenzo
Gallo, Maurizio
Casini, Cecilia
Fallani, Neri
Stabile, Mario
Barbero, Valentina
Murialdo, Roberto
Tixi, Lucia
Cappuccio, Margherita
Cuboni, Andrea
Sivieri, Irene
Fornarini, Giuseppe
De Maria, Andrea
Ballestrero, Alberto
Zoppoli, Gabriele
author_sort Ravera, Francesco
collection PubMed
description BACKGROUND AND RATIONALE: Little is known about SARS-CoV-2 seroconversion in asymptomatic patients affected by solid cancer, and whether it is associated with specific transcriptomics changes in peripheral blood mononuclear cells (PBMC). METHODS: Patients affected by solid cancer treated in a top comprehensive cancer center in Italy during the first COVID-19 pandemic wave, and negative for COVID-19-symptoms since the first detection of COVID-19 in Italy, were prospectively evaluated by SARS-CoV-2 serology in the period between April 14th and June 23rd 2020. Follow-up serologies were performed, every 21–28 days, until August 23rd 2020. All SARS-CoV-2 IgM + patients underwent confirmatory nasopharyngeal swab (NPS). PBMCs from a subset of SARS-CoV-2 IgM + patients were collected at baseline, at 2 months, and at 7 months for transcriptome sequencing. RESULTS: SARS-CoV-2 serology was performed on 446 of the 466 recruited patients. A total of 14 patients (3.14%) tested positive for at least one SARS-CoV-2 immunoglobulin in the period between April 14th and August 23rd 2020. Incidence of SARS-CoV-2 IgM decreased from 1.48% in the first month of the accrual to 0% in the last month. Viral RNA could not be detected in any of the NPS. PBMC serial transcriptomic analysis showed progressive downregulation of interleukin 6 upregulated signatures, chemokine-mediated signaling and chemokine-chemokine receptor KEGG pathways. B- and T-cell receptor pathways (p-values = 0.0002 and 0.017 respectively) were progressively upregulated. CONCLUSIONS: SARS-CoV-2 seroconversion rate in asymptomatic patients affected by solid cancer is consistent with that of asymptomatic COVID-19 assessed in the general population through NPS at the peak of the first wave. Transcriptomic features over time in IgM + asymptomatic cases are suggestive of previous viral exposure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03429-0.
format Online
Article
Text
id pubmed-9107211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91072112022-05-16 Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study Ravera, Francesco Borea, Roberto Cirmena, Gabriella Dameri, Martina Ferrando, Lorenzo Gallo, Maurizio Casini, Cecilia Fallani, Neri Stabile, Mario Barbero, Valentina Murialdo, Roberto Tixi, Lucia Cappuccio, Margherita Cuboni, Andrea Sivieri, Irene Fornarini, Giuseppe De Maria, Andrea Ballestrero, Alberto Zoppoli, Gabriele J Transl Med Research BACKGROUND AND RATIONALE: Little is known about SARS-CoV-2 seroconversion in asymptomatic patients affected by solid cancer, and whether it is associated with specific transcriptomics changes in peripheral blood mononuclear cells (PBMC). METHODS: Patients affected by solid cancer treated in a top comprehensive cancer center in Italy during the first COVID-19 pandemic wave, and negative for COVID-19-symptoms since the first detection of COVID-19 in Italy, were prospectively evaluated by SARS-CoV-2 serology in the period between April 14th and June 23rd 2020. Follow-up serologies were performed, every 21–28 days, until August 23rd 2020. All SARS-CoV-2 IgM + patients underwent confirmatory nasopharyngeal swab (NPS). PBMCs from a subset of SARS-CoV-2 IgM + patients were collected at baseline, at 2 months, and at 7 months for transcriptome sequencing. RESULTS: SARS-CoV-2 serology was performed on 446 of the 466 recruited patients. A total of 14 patients (3.14%) tested positive for at least one SARS-CoV-2 immunoglobulin in the period between April 14th and August 23rd 2020. Incidence of SARS-CoV-2 IgM decreased from 1.48% in the first month of the accrual to 0% in the last month. Viral RNA could not be detected in any of the NPS. PBMC serial transcriptomic analysis showed progressive downregulation of interleukin 6 upregulated signatures, chemokine-mediated signaling and chemokine-chemokine receptor KEGG pathways. B- and T-cell receptor pathways (p-values = 0.0002 and 0.017 respectively) were progressively upregulated. CONCLUSIONS: SARS-CoV-2 seroconversion rate in asymptomatic patients affected by solid cancer is consistent with that of asymptomatic COVID-19 assessed in the general population through NPS at the peak of the first wave. Transcriptomic features over time in IgM + asymptomatic cases are suggestive of previous viral exposure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03429-0. BioMed Central 2022-05-14 /pmc/articles/PMC9107211/ /pubmed/35568887 http://dx.doi.org/10.1186/s12967-022-03429-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ravera, Francesco
Borea, Roberto
Cirmena, Gabriella
Dameri, Martina
Ferrando, Lorenzo
Gallo, Maurizio
Casini, Cecilia
Fallani, Neri
Stabile, Mario
Barbero, Valentina
Murialdo, Roberto
Tixi, Lucia
Cappuccio, Margherita
Cuboni, Andrea
Sivieri, Irene
Fornarini, Giuseppe
De Maria, Andrea
Ballestrero, Alberto
Zoppoli, Gabriele
Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study
title Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study
title_full Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study
title_fullStr Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study
title_full_unstemmed Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study
title_short Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study
title_sort incidence and immunomic features of apyretic covid-19 in patients affected by solid tumors: a prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107211/
https://www.ncbi.nlm.nih.gov/pubmed/35568887
http://dx.doi.org/10.1186/s12967-022-03429-0
work_keys_str_mv AT raverafrancesco incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT borearoberto incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT cirmenagabriella incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT damerimartina incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT ferrandolorenzo incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT gallomaurizio incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT casinicecilia incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT fallanineri incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT stabilemario incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT barberovalentina incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT murialdoroberto incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT tixilucia incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT cappucciomargherita incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT cuboniandrea incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT sivieriirene incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT fornarinigiuseppe incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT demariaandrea incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT ballestreroalberto incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy
AT zoppoligabriele incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy